Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. - Wikidata - wikimedia - TriplyDB

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

http://www.wikidata.org/entity/Q38120850

about

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Progress toward overcoming hypoxia-induced resistance to solid tumor therapy Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors Switching off malignant mesothelioma: exploiting the hypoxic microenvironment ABC transporters in CSCs membranes as a novel target for treating tumor relapse.AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy Modulation of the tumor vasculature and oxygenation to improve therapy Biological evaluation of the toxicity and the cell cycle interruption by some benzimidazole derivatives.Physiologic hypoxia and oxygen homeostasis in the healthy intestine. A Review in the Theme: Cellular Responses to Hypoxia.Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.Hypoxia and Mucosal Inflammation.The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes Recent updates in utilizing prodrugs in drug delivery (2013-2015).Hypoxia-Sensitive Materials for Biomedical Applications.Modulating tumor hypoxia by nanomedicine for effective cancer therapy.Hypoxia: A Double-Edged Sword in Cancer Therapy.Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation.Advances in Stimulus-Responsive Polymeric Materials for Systemic Delivery of Nucleic Acids.18F-Fluoromisonidazole in tumor hypoxia imaging.The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.The efficacy of Apaziquone in the treatment of bladder cancer.Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.Detection of DT-diaphorase Enzyme with a ParaCEST MRI Contrast Agent.Tailoring the properties of a hypoxia-responsive 1,8-naphthalimide for imaging applications.Synthesis and Evaluation of Radiolabeled Phosphoramide Mustard with Selectivity for Hypoxic Cancer Cells.Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment

P2860

Q26774750-625D181A-A944-4105-B890-FF33F6512A93 Q26796405-648D8729-7AE3-4271-AB41-C9CAD1842EAA Q27009437-08565DAE-F49C-444F-8F56-DE1D6108C324 Q28553729-6B8439EC-40F4-4926-9227-06CC4352A363 Q29248727-5DD5148B-C03D-432E-8E08-27A6445BE3A4 Q33879326-9CFC368E-7764-4603-A336-C1B9668781E2 Q34482552-534A8FE0-D39A-409D-BF6E-BDBDD3A31971 Q35116993-B2F928C9-AF00-46DD-B7EE-4B4C9A375A1D Q35920685-8A34BBDD-58E8-420C-A20A-4BF90299E367 Q35942287-2F7F637E-12C2-44F8-B921-708CBB45E07E Q36066325-3EB9D774-84B9-4B3D-BCE3-1D2B4229CA89 Q36072569-C71E2D2E-1DA3-48BC-B0A0-02EBE8951E2D Q36955828-34AA0E47-E5FD-4BF4-A71C-03E9BE75493C Q37550577-16390378-0BFE-4291-A47A-846F44137243 Q37565506-BD5047AE-B9A0-4F5F-AA11-2E3B9067A37B Q37594215-3FB17470-2092-4F29-83C7-8F72A7A15FD7 Q38702949-2A406DED-7262-42B2-969D-964DED14D206 Q38754932-ECF38825-A11F-4945-8CDA-AFE201D1DD15 Q38961080-564B1119-3DC5-42D6-8540-9AFD8BBD0C4A Q39002822-EBEB1564-C7EA-45DE-8387-3C3F3EF1F7E9 Q39458957-614E955E-F09F-47C9-B75E-07D1DCAC1A28 Q42107713-EA42445A-67EC-47B5-B593-CF884B07A81B Q46244037-1D31EC1B-BFA0-4DBB-8785-997FF5C9EDBD Q47135488-3FC5A613-A5E7-40F2-A03D-FFF5930923EC Q47763534-DB67AF81-D111-45C2-9796-49058277F953 Q47769995-AAC69810-5833-4EDE-942D-C290D40B0291 Q47789499-3F1DC8C2-2976-4CA2-BEEA-76609880586D Q48013511-23C3A6E5-B84F-4CA0-809C-84FFA224CEE1 Q48331849-EA766A38-973F-4A9A-A7B0-675A740930B7 Q50182528-1EE02B06-42CA-4A0E-A2C9-E41D669A00CD Q52743608-2F219B55-EFEE-4B5D-BC8E-05D78FEFDB0B Q57483703-0616DD2D-F76D-4CA5-8749-D57E3357D494

P2860

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

http://www.wikidata.org/entity/Q38120850

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

@en

type

label

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

@en

prefLabel

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

@en

P1433

Q38120850-677B0E97-8A3A-4708-A8EA-65A45CA17D7A

P1476

Q38120850-35DB2FF9-2852-4D30-BD2C-D209725FA136

P2093

Q38120850-345952C5-1277-4F88-97AE-1CBBC720CB19

Q38120850-3B41A505-C2EC-4C66-91D2-3D18F2D74499

Q38120850-78ABABCB-CEFC-4A3B-B9A2-D57F67594EA6

Q38120850-82AF5B12-B576-4981-BD53-E98F7D277F76

Q38120850-9752CB38-84AC-4A33-AFF2-733069507B56

Q38120850-C996CB62-0F18-4B03-BF81-12F8B775F08C

Q38120850-F1F20E7B-C27A-4EED-9A16-DBBE64E6863F

Q38120850-F40CF139-EB7B-43D4-AB0D-31314208C1B7

Q38120850-F757148C-FBDE-4249-856E-4B1C6CE1093C

P275

Q38120850-AB656321-FF33-4198-9E84-9810323D8C7A

P2860

Q38120850-0D2EA336-FA5A-494D-B179-E0F39A04A508

Q38120850-0F7EABE2-D126-4E94-A2D5-867E1C87FECE

Q38120850-1196397B-7D06-4F7F-8BAC-311D392E7146

Q38120850-136C4991-F88B-4BDF-8DAA-1AA596F47FA5

Q38120850-1923978C-F88C-4BD5-8961-4FF8D4102093

Q38120850-1E01A3FB-933B-49B4-A48C-A27597A13F06

Q38120850-25731616-A628-46BC-94E0-850C5E8BFCD2

Q38120850-27787BF7-D2E1-43FE-9654-1D28A0FF2369

Q38120850-28486D89-DE4A-4A0D-89F4-17782EF5B57C

Q38120850-2F360BD0-82FD-4D44-9095-5F7E754FE72B

P304

Q38120850-F6910FDD-6EDA-4496-AEDE-0B01EB1756A8

P31

Q38120850-3E785D27-93A1-4266-951A-E6FB27F837B7

Q38120850-9BCF15F6-FEFB-4450-9EDE-874A1D7F9D73

P356

Q38120850-1DB8723E-31B4-44EA-BB70-9ABC4E44C1D7

P433

Q38120850-58BD7CCF-6D0E-4DD6-BD42-541458D64A0A

P478

Q38120850-E833D7FB-6BF0-461A-B1BD-43BCD22CBD95

P50

Q38120850-EC22636D-C554-451C-95E6-D0C242A9E51A

P5008

Q38120850-5DFBD846-DA22-4D60-8A5C-C8CEC736F635

P577

Q38120850-7B20F50F-4DDE-4B2D-AFBC-0810909B2B25

Q38120850-D2B08241-5F50-4A8E-8957-A97F6237DAE8

P5875

Q38120850-B449CD89-9DE3-42EA-9F52-4AEBDBA3BAE2

P698

Q38120850-3451B1E2-202F-459A-BBCF-000114D95A31

P921

Q38120850-2452EDFE-0D1C-49E5-B45D-6479F3C76D98

Q38120850-71EFF195-7499-4CC4-BC1A-48B55D03F4F5

Q38120850-92A29B56-3D7C-4D36-871C-C7C60658E1EA

P932

Q38120850-82BDE7AD-81A0-4563-879C-21A2DC792488

P356

P1433

Chinese Journal of Cancer

P1476

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

@en

P2093

Alexandra M Mowday

http://www.w3.org/2001/XMLSchema#string

Amir Ashoorzadeh

http://www.w3.org/2001/XMLSchema#string

Christopher P Guise

http://www.w3.org/2001/XMLSchema#string

Dong-Hai Wu

http://www.w3.org/2001/XMLSchema#string

Jeff B Smaill

http://www.w3.org/2001/XMLSchema#string

Ke Ding

http://www.w3.org/2001/XMLSchema#string

Ran Yuan

http://www.w3.org/2001/XMLSchema#string

Wan-Hua Lin

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

P2860

NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

Hypoxia in cancer: significance and impact on clinical outcome

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9

Hypoxia--a key regulatory factor in tumour growth

Drug resistance and the solid tumor microenvironment

Drug penetration in solid tumours

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

P304

80-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5732/CJC.012.10285

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Adam V. Patterson

P5008

P577

2013-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

248704441

http://www.w3.org/2001/XMLSchema#string

P698

23845143

http://www.w3.org/2001/XMLSchema#string

P921

pharmaceutical preparation

P932

3935009

http://www.w3.org/2001/XMLSchema#string